/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The Readout Loud
  2. Definium's new psychedelics data, and a reprieve for international scientists
Definium's new psychedelics data, and a reprieve for international scientists

Definium's new psychedelics data, and a reprieve for international scientists

The Readout Loud · Sep 17, 2026

Psychedelics go mainstream with new data and Big Pharma deals, while restrictive immigration policies threaten the future of US science.

The Administrative "Policy of Uncertainty" Is Driving Away International Scientists More Than Any Single Rule

Even with court injunctions blocking specific anti-immigration rules, the unpredictable and hostile environment created by the administration has become a policy in itself. This "uncertainty policy" has eroded trust and is a more powerful deterrent for international scientists than any individual regulation.

Definium's new psychedelics data, and a reprieve for international scientists thumbnail

Definium's new psychedelics data, and a reprieve for international scientists

The Readout Loud·2 months ago

Novo Nordisk's Rebrand Signals a Pivot From Medicalizing Obesity to Selling a Consumer Lifestyle Product

The change to "Novo" and marketing language prioritizing "consumer" over "patient" reveals a two-step strategy. After successfully establishing obesity as a serious disease to secure insurance reimbursement, Novo is now shifting to marketing its drugs directly to consumers as lifestyle brands.

Definium's new psychedelics data, and a reprieve for international scientists thumbnail

Definium's new psychedelics data, and a reprieve for international scientists

The Readout Loud·2 months ago

A Rare Disease Drug's Mechanism Is Pivoting to Address Blockbuster Obesity Drug Side Effects

ScholarRock's newly approved drug for the rare disease spinal muscular atrophy blocks myostatin to prevent muscle loss. This same mechanism is now being redeployed as a major strategy to counteract the muscle loss side effect of GLP-1 obesity drugs, potentially opening a massive new market.

Definium's new psychedelics data, and a reprieve for international scientists thumbnail

Definium's new psychedelics data, and a reprieve for international scientists

The Readout Loud·2 months ago

Psychedelics' Logistical Burden Will Split the Market Between Long-Session and Fast-Acting Drugs

The significant clinical time commitment for psychedelic therapies like LSD, which can require 8-10 hours of monitoring, is a major commercialization hurdle. This will likely bifurcate the market, creating high demand for faster-acting compounds like 5-MEO-DMT that reduce the logistical and cost burden on clinics and patients.

Definium's new psychedelics data, and a reprieve for international scientists thumbnail

Definium's new psychedelics data, and a reprieve for international scientists

The Readout Loud·2 months ago

Big Pharma Acquisitions Confirm Psychedelics Have Shifted From Fringe Science to Mainstream Strategy

Recent acquisitions, such as Eli Lilly buying Atai and AbbVie buying Gigamesh, are the clearest signal that psychedelic therapies are no longer a niche R&D area. Major pharmaceutical companies now view the space as a core part of their growth strategy and a substantial business opportunity.

Definium's new psychedelics data, and a reprieve for international scientists thumbnail

Definium's new psychedelics data, and a reprieve for international scientists

The Readout Loud·2 months ago